Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd. (ROIV), executed a sale of 200,000 shares on May 22, 2026. The transaction, valued at approximately $6.05 million, occurred at an average price of $30.27 per share.
This marks Venker's second significant sale of Roivant Sciences shares in recent weeks, following a similar transaction on April 20, 2026, where he sold 200,000 shares for approximately $5.92 million. Other notable insider sales from Roivant Sciences in the past few months include transactions by Matthew Gline, Jennifer Humes, and Meghan Fitzgerald.
Insider sales can be driven by various factors, including portfolio diversification, tax obligations, or pre-arranged trading plans, and do not necessarily reflect a negative outlook on the company's future performance.